Should You Buy Lisata Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Lisata Therapeutics, Inc. (LSTA) occupies a solid middle-ground position with a Quality of Company score of 5.5/10. At the current market price of $1.54, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 0 of 0 CirclFi valuation models project upside for Lisata Therapeutics, Inc. (LSTA) at $1.54 — the models are evenly split, with a Quality Score of 5.5/10 and Value-Trap risk of 28/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Lisata Therapeutics, Inc. (LSTA) in 2026?
What Is the Bull Case vs the Bear Case for Lisata Therapeutics, Inc. (LSTA)?
| Bull case | Bear case |
|---|---|
| No active model projects meaningful upside for LSTA at $1.54. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for LSTA. The low Value Trap score paints a constructive picture. |
How Does LSTA Compare to Its Biotechnology Peers?
Valuation data pages: OCS · LENZ · SPRY · SRRK · ADXN · GNLX · CNSY · ACTU · FHTX · EXEL · INCY
Which Other Stocks Score Like LSTA on Quality?
Closest companies to LSTA’s Quality of Company score of 5.5/10, across all industries.
Which Biotechnology Screens Does LSTA Appear In?
So Is Lisata Therapeutics, Inc. (LSTA) Worth Buying in 2026?
Lisata Therapeutics, Inc. currently lacks sufficient model coverage for a definitive valuation conclusion. We recommend monitoring as additional SEC filing data becomes available.
These are quantitative model outputs, not investment recommendations. Lisata Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About LSTA Stock?
Should I buy LSTA stock right now?
Based on CirclFi's multi-model analysis, 0 of 0 models see upside for LSTA at $1.54. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Lisata Therapeutics, Inc.?
Key risks include: limited model coverage (0/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does LSTA compare to its competitors?
Among Biotechnology peers, LSTA holds a Quality Score of 5.5/10. Comparable companies include OCS (QOC 5.5), LENZ (QOC 5.5), SPRY (QOC 5.5). The relative ranking helps investors identify whether LSTA offers better fundamental quality than alternatives in the same sector.
Is LSTA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LSTA's Quality Score of 5.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy LSTA at?
CirclFi does not provide target buy prices or price alerts. However, our 0 active models produce fair value estimates ranging from — to —. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for LSTA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad